SLC52A2 and renal tubular dysgenesis of genetic origin: Considering the recent advances in the field of gene therapy, we designed and tested a AAV9-SLC52A2 gene supplementation therapy which would be efficacious on all RTD patients independently to the carried mutations and/or their responsiveness to RF treatment.